Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma
Authors
Keywords
Overall Response Rate, Vemurafenib, Stage IIIB, Isolate Limb Perfusion, Talimogene Laherparepvec
Journal
BIODRUGS
Volume 30, Issue 5, Pages 461-468
Publisher
Springer Nature
Online
2016-08-11
DOI
10.1007/s40259-016-0189-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA
- (2017) J.J. Nemunaitis et al. ANNALS OF ONCOLOGY
- Metastatic Melanoma – A Review of Current and Future Treatment Options
- (2015) E Maverakis et al. ACTA DERMATO-VENEREOLOGICA
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Abstract 258: Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade
- (2015) Julia Piasecki et al. CANCER RESEARCH
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
- (2015) F. J. Kohlhapp et al. CLINICAL CANCER RESEARCH
- Oncolytic Virus Immunotherapy for Melanoma
- (2015) Neal Dharmadhikari et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
- (2015) Kevin J Harrington et al. Expert Review of Anticancer Therapy
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Society for Melanoma Research 2015 Congress
- (2015) Pigment Cell & Melanoma Research
- Innate and adaptive immunity contribute to the anti-tumor mechanisms of action of OncoVEXmGM-CSF
- (2015) Keegan Cooke et al. Journal for ImmunoTherapy of Cancer
- Oncovex MGM-CSF –mediated regression of contralateral (non-injected) tumors in the A20 murine lymphoma model does not involve direct viral oncolysis
- (2015) Keegan Cooke et al. Journal for ImmunoTherapy of Cancer
- Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma
- (2014) Darshil J. Shah et al. MAYO CLINIC PROCEEDINGS
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies
- (2012) Md. Zeyaullah et al. PATHOLOGY & ONCOLOGY RESEARCH
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started